People still believe that hyperbaric oxygen therapy only works at higher pressures. Most of them are only practicing with higher pressure protocols and have not taken the time to go through the steady influx of all the recent data and research making its way into current medical journals and publications. If they did, they would very quickly be able to see that lower pressures can provide very powerful effects, and sometimes even more powerful than those observed with higher pressures; the latter was just the case in a landmark study released in 2013. This study was published in the UHMS journal (a mainstream, peer reviewed, hyperbaric medical journal) and looked at the difference between 2.4 ATA (higher pressure HBOT) and 1.5 ATA (lower pressure HBOT). The results were stunning in virtually all areas observed. Researchers observed 92 inflammatory genes and this is what they quoted:

"Interestingly, oxygen at 1.5 atm abs affected many genes much more strongly than oxygen at 2.4. The reasons for this effect are unknown, but it does raise questions about the most appropriate treatment pressures for inflammatory conditions"

It was landmark study for lower pressure protocols, because it clearly demonstrated that the lower pressure protocols (1.5 ATA) had much stronger effects in the inflammatory genes observed than the higher pressures (2.4 ATA). <view study>     Read Less

Hyperbaric oxygen therapy has received a lot of attention over the past 20 years for helping patients following traumatic events. Though this therapy is not part of the approved medical treatments for traumatic brain injuries, both clinical research data and case reports have documented that there is a potential benefit from this procedure. Of late, mild traumatic brain injuries (mTBI's) have been in the news, due to the increasing understanding and concerns with concussions, particularly with athletes in sporting events. This study took 56 patients who had prolonged post-concussion syndrome following 1-5 years post mTBI. A "typical" program of hyperbaric oxygen therapy (this HBOT protocol included 40 treatment sessions (5 days/week), 60 minutes each, with 100% oxygen at 1.5 ATA) was given to the treatment group, which demonstrated significant improvements. These results led the researchers of this study to conclude that "HBOT can induce neuroplasticity leading to repair of chronically impaired brain functions and improved quality of life in mTBI patients with prolonged PCS at late chronic stage" <view study>     Read Less

Hyperbaric oxygen therapy is currently a recognized treatment for osteonecrosis. This is a condition where their is reduced blood flow and consequent breaking down of the bone. This study looked at the relationship of osteoclasts and hyperbaric oxygen exposure. Osteoclasts are cells that break down bone and are in constant battle with osteoblasts, which are cells that build bone. The results showed that hyperbaric exposure caused a significant reduction in osteoclasts formation and subsequently resulted in reduction in bone loss <view study> Read Less

The chemotherapy drug Gemcitabine, is used for treating certain cancers, including advanced pancreatic cancer. It delivers oxygen to the tumors and thus makes the chemo drug more toxic to the targeted cancer, allowing a greater cancer killing effect. This results of this study (published in the anticancer research journal) confirmed this effect, and showed a significant enhancement of Gemcitabine’s cancer killing effect when hyperbaric oxygen therapy was applied concurrently <view study> Read Less